- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00566267
A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet (LOCUST)
November 30, 2007 updated by: Merck Sharp & Dohme LLC
People who follow a low-carbohydrate diet typically experience a decrease in triglycerides and increase in HDL-C level, but fail to lower their LDL cholesterol (LDL-C).
Such patients may require lipid-lowering therapy.
Statins may not be the most effective strategy for patients on this diet, since they typically consume a greater amount of saturated fat and cholesterol.
Absorbed cholesterol may contribute more to their circulating plasma LDL-C.
We hypothesize that patients following a low carbohydrate diet would experience a significantly greater decrease in LDL-C by taking ezetimibe 10 mg, a drug that blocks cholesterol uptake in the intestine, in addition to simvastatin 20 mg, when compared to taking simvastatin 20 mg alone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 2
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Moderately obese with hyperlipidemia
Exclusion Criteria:
- Recent unstable heart or lung condition
- Current use of other lipid modifying drugs
- Hepatic disease
- Pregnancy or lactation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 2
Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
|
see protocol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
LDL cholesterol
Time Frame: 8 weeks of treatment
|
8 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Other lipid measures
Time Frame: 8 weeks of treatment
|
8 weeks of treatment
|
|
Safety and tolerability
Time Frame: 8 weeks treatment
|
8 weeks treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Frederick F Samaha, M.D., Philadelphia Vamc
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2006
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
November 29, 2007
First Submitted That Met QC Criteria
November 30, 2007
First Posted (Estimate)
December 3, 2007
Study Record Updates
Last Update Posted (Estimate)
December 3, 2007
Last Update Submitted That Met QC Criteria
November 30, 2007
Last Verified
November 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00887
- MIRB Number: 00887
- PROM # 0025
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingPrimary Hyperlipidemia
-
Gan & Lee Pharmaceuticals.RecruitingPrimary HyperlipidemiaChina
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Chengdu Diao Jiuhong Pharmaceutical FactoryRecruiting
-
Washington University School of MedicineRecruitingHypercholesterolemia and HyperlipidemiaUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingHypercholesterolemia and HyperlipidemiaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Dr. Md. Alimur RezaRecruitingHyperlipidemia (E.G., Hypercholesterolemia)Bangladesh
Clinical Trials on simvastatin 20 mg/ezetimibe
-
Organon and CoMerck Shering-Plough JV StudyCompleted
-
Organon and CoSchering-PloughCompletedCoronary Disease | Hypercholesterolemia
-
University Hospital FreiburgEssex Pharma GmbHCompletedHypercholesterolemia | Diabetes Mellitus Type 2Germany
-
Ache Laboratorios Farmaceuticos S.A.CompletedDyslipidemia | HypercholesterolemiaBrazil
-
Organon and CoSchering-PloughCompletedCoronary Disease | Diabetes Mellitus, Type 2 | Hypercholesterolemia
-
Hue University of Medicine and PharmacyUniversità degli Studi di SassariUnknownChronic Kidney Diseases | HypercholesterolemiaVietnam
-
Instituto Nacional de Ciencias Medicas y Nutricion...Merck Sharp & Dohme LLCWithdrawnCardiovascular Diseases | Hyperlipidemia
-
Organon and CoCompletedDiabetes Mellitus | Cardiovascular Disorder
-
University of Sao PauloCompleted
-
University of OxfordNational Health and Medical Research Council, Australia; Merck Sharp & Dohme... and other collaboratorsCompleted